Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

The Concrete is Pouring, the Construction Workers are on the Ground: New Nuclear Medicine Production Facility Underway

publication date: Feb 19, 2015
 | 
author/source: ANSTO

Australia’s new nuclear medicine manufacturing facility is taking shape – a project which will enable Australia to help meet world demand for the most common radionuclide used in nuclear medicine, Molybdenum-99.

ANSTOThe next critical steps in the development of Australia’s new nuclear medicine production facility are now complete, with the bulk of the excavation work finalised and more than 1900m3 of concrete poured, and more than 350 tonnes of steel reinforcement in place.

The ANSTO Nuclear Medicine (ANM) project, underway at the Australian Nuclear Science and Technology Organisation (ANSTO), represents a $168.8 million investment by the Australian Government.

Through it, Australia will secure continued supplies of nuclear medicines for the domestic market, and the ability to contribute significantly to international demand.

Currently ANSTO produces around 10,000 patient doses of nuclear medicines per week which is distributed to more than 250 hospitals and nuclear medicine centres across Australia, as well as shipping product internationally.

The current world demand for Technetium-99m (Tc-99m), which is the decay product of Molybdenum-99 (Mo-99) is estimated to be approximately 40 million patient doses per annum.

Once fully operational, Australia’s new Mo-99 manufacturing plant will enable ANSTO to significantly increase its production capabilities, and to supply up to 25-30% of global demand.

“We are part way through the phased process of pouring the ground floor on this project” said ANM Board Chairman, Doug Cubbin.

“Our project remains on schedule and budget. We are confident the planned operational date is achievable as our facility will use proven production methods already demonstrated at the scale we are building our facility for.

“We expect that once operational it will deliver a medical dividend to the world, and a financial dividend to Australia.

“Importantly, through this project, Australia will continue to produce nuclear medicine using Low-Enriched Uranium, which is proliferation-proof – contributing significantly to regional nuclear security goals.”


more about ANSTO


 

 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events